Intuitive Machines partners with Houston college for workforce training

space training

Intuitive Machines, Rhodium Scientific and San Jacinto College will partner to train future workers for space-based pharma recovery. Photo courtesy Intuitive Machines.

Intuitive Machines, a Houston-based space technology, infrastructure and services company, has forged a partnership with San Jacinto College to develop a program for training workers to handle biopharmaceutical materials delivered to Earth on Intuitive Machines’ re-entry vehicle.

Intuitive Machines is working with biotech company Rhodium Scientific on the project. Rhodium, also based in Houston, is developing biomanufacturing payloads for Intuitive Machines’ re-entry vehicle.

“Delivering life-improving pharmaceuticals from orbit is only valuable with reliable recovery and processes on Earth,” Tim Crain, chief technology officer at Intuitive Machines, said in a news release. “That requires more than a spacecraft — it demands the workforce, facilities, and regulatory alignment to support safe, repeatable operations. San Jacinto College has the credibility and technical depth to make this vision a reality.”

San Jacinto College provides training certified by the National Institute for Bioprocessing Research and Training. Christopher Wild, assistant vice chancellor and vice president of biotechnology at San Jacinto College, said that with this certification and the college’s presence at Houston Spaceport, the school “is uniquely positioned to train the workforce needed (for) commercial space-based pharma recovery.”

The first-phase grant supporting Intuitive Machines’ Earth re-entry program will culminate in a full-scale mockup tailored to real payloads and use cases in early 2026.

Intuitive Machines said the collaborations with San Jacinto College and Rhodium “aim to align future landing infrastructure, research opportunities, and funding pathways that deliver lasting economic impact from space.”

From Your Site Articles
March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A

cha-ching

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston's surge in new startups cools since pandemic peak, study shows

by the numbers

Startup activity in the Houston metro area has dipped since its pandemic peak, according to a new study.

Dating back to 2005, the volume of applications to form new businesses in the Houston area hit its highest level in 2021 (151,804). Since then, though, the application volume has fallen, according to the study, conducted by business debt collection agency The Kaplan Group. Here's the breakdown from the last few years:

  • Applications dropped to 130,011 in 2022
  • Climbed to 145,926 in 2023
  • Dropped again to 138,595 in 2024

Looking at the Houston area’s figures another way, the 2024 total surpassed the 2015-19 average by roughly 60 percent to 90 percent, the study shows.

Dallas-Fort Worth has seen similar startup declines (162,312 in 2021 vs. 153,378 in 2024), but the San Antonio metro area recorded higher application volume in 2023 and 2024 (37,412 and 35,798, respectively) than it did in 2021 (34,208).

The story is different in the Austin metro area. Application volume in 2023 and 2024 (53,200 and 59,190, respectively) exceeded the 2021 total (47,106).

The picture for startup activity in Texas’ four major metros deviates from the nationwide picture.

“America’s real viral trend is entrepreneurship,” says The Kaplan Group. “New business formations are reaching an all-time high across the country.”

In the U.S., per-month business formations soared 435 percent from 2004 (89,561) to 2025 (478,805), the study says.

Amid the growth of startup activity, business bankruptcies in the U.S. have plummeted almost 74 percent since 2004, according to The Kaplan Group.

“The country’s business scene has grown both more resilient and more ambitious in the past two decades,” the collection agency says.

12+ can't-miss Houston business and innovation events for September

where to be

Editor's note: Houston's business and innovation events are back in session. From the return of Houston Energy and Climate Startup Week to a send-off for an impactful innovation leader and several health conferences, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Sept. 5-7 — Houston Hackathon

Impact Hub Houston is bringing back the Houston Hacakthon this month, where developers of all skill sets can work together to propose solutions to some of the Bayou City’s most pressing issues. The event is focused on ideating, designing, and developing both policy-based and tech solutions to improve Houston.

This event starts Saturday, Sept. 5, at noon at the Ion. Register here.

Sept. 8 — Community Celebration: A Send-Off for Paul Cherukuri

Come out to the Ion to celebrate Paul Cherukuri, Rice’s first chief innovation officer, whose visionary leadership has left a lasting impact on Houston’s innovation ecosystem. Cherukuri is leaving the university to accept a position at the University of Virginia. Hear remarks from Cherukuri and enjoy a networking reception following the talk.

This event is Monday, Sept. 8, from 2:30-5:00 p.m. at the Ion. Register here

Sept. 11 — Houston Methodist Leadership Speaker Series – Dr. Evan Collins

The Houston Methodist Tech Hub at the Ion will host its recurring leadership speaker series, this time featuring Dr. Evan Collins, chief of the Houston Methodist Hand & Upper Extremity Center at Houston Methodist and the Houston Methodist Center for Innovation's first innovator-in-residency. Collins will present on the creative process of innovation.

This event is Thursday, Sept. 11, from 4:45-6 p.m. at the Ion. Register here.

Sept. 12 — Future of Space

The Greater Houston Partnership’s 2025 Future of Space event will feature a keynote address by Vanessa E. Wyche, acting associate administrator of NASA. In her new role, Wyche serves as NASA’s chief operating officer, leading more than 18,000 employees and overseeing an annual budget exceeding $25 billion. Discussions will highlight how Houston’s space ecosystem is driving economic growth, technological innovation and new opportunities across the region and the nation.

The event is Friday, Sept. 12, from noon-1:30 p.m. at the Royal Sonesta. Find more information here.

Sept. 15-19 — Houston Energy and Climate Startup Week

Houston Energy and Climate Startup Week returns for its second year, with panels, happy hours and pitch days focused on the energy transition. The week features major events, including the Energytech Nexus Pilotathon, the Rice Alliance Energy Tech Venture Forum, Halliburton Labs Finalists Pitch Day and many others. See a preview of the week on our sister site EnergyCapitalHTX.com and learn more in the event listings below.

This event starts Monday, Sept. 15. The Ion District will host many of the week's events. Find more information here.

Sept. 16 — Energytech Nexus Pilotathon

Grab breakfast and take in keynotes and panels by leaders from New Climate Ventures, V1 Climate, Halliburton, Energy Tech Nexus and many others during Houston Energy & Climate Week. Then hear pitches during the Pilotathon, which targets startups ready to implement pilot projects within six to 12 months.

This event is Tuesday, Sept. 16, from 8 a.m.-5 p.m. at GreenStreet. Get tickets here.

Sept. 16 — Meet the Activate Houston Cohort 2025 Fellows

Meet Activate's latest cohort, which was named this summer, and also learn more about its 2024 group during Houston Energy & Climate Week.

This event is Tuesday, Sept. 16, at 5 p.m. at the Ion. Register here.

Sept. 17 — Green ICU Conference: Sustainability in Health Care for a Healthier Future

Houston Methodist will host its inaugural Green ICU Conference during Houston Energy & Climate Week. The conference is designed to bring together healthcare professionals, industry leaders, policymakers and innovators to explore solutions for building a more sustainable healthcare system.

This event is Wednesday, Sept. 17. from 8 a.m.-3 p.m. at TMC Helix Park. Register here.

Sept. 18 — Rice Alliance Energy Tech Venture Forum

Hear from clean energy startups from nine countries and 19 states at the 22nd annual Energy Tech Venture Forum during Houston Energy & Climate Week. The 12 companies that were named to Class 5 of the Rice Alliance Clean Energy Accelerator will present during Demo Day to wrap up their 10-week program. Apart from pitches, this event will also host keynotes from Arjun Murti, partner of energy macro and policy at Veriten, and Susan Schofer, partner at HAX and chief science officer at SOSV. Panels will focus on corporate innovation and institutional venture capital.

This event is Thursday, Sept. 18, from 7:30 a.m.-5 p.m. at Rice University’s Jones Graduate School of Business. Register here.

Sept. 18 — ACCEL Year 3 Showcase

Celebrate Advancing Climatetech and Clean Energy Leaders Program, or ACCEL, an accelerator program for startups led by BIPOC and other underrepresented founders from Greentown Labs and Browning the Green Space. Two Houston companies and one from Austin are among the eight startups to be named to the 2025 group. Hear startup pitches from the cohort, and from Greentown's Head of Houston, Lawson Gow, CEO Georgina Campbell Flatter and others. This event is part of Houston Energy & Climate Week.

This event is Thursday, Sept. 18, from 5-8 p.m. at Greentown Labs. Get tickets here.

Sept. 19 — Halliburton Labs Finalists Pitch Day

Hear from Halliburton Labs' latest cohort of entrepreneurs during Houston Energy & Climate Week. The incubator aims to advance the companies’ commercialization with support from Halliburton's network, facilities and financing opportunities. Its latest cohort includes one company from Texas.

This event is Friday, Sept. 19, from 8 a.m.-noon at The Ion. Register here.

Sept. 21-25 — AI in Health Conference

The Ken Kennedy Institute at Rice University will present the fourth annual AI in Health Conference, which aims to bridge the gap between artificial intelligence and real-world health outcomes. The event will explore the current landscape of artificial intelligence in health and present a research-driven outlook for the future of computational health innovation.

This conference is from Tuesday, Sept. 23, to Wednesday, Sept. 24. Additional workshops will be offered on Monday, Sept. 22, and Thursday, Sept. 25. The events will be held at the BioScience Research Collaborative at Rice University. Find more information here.

Sept. 25 — Industrial AI Nexus Connect

InnovateEnergy and Industrial AI Nexus will host a talk by Matthew Alberts, manager of innovation and emerging technologies at Southern Company and author of "The Gen AI Manufacturing Revolution: Smarter Factories, Enhanced Products, and Reduced Costs." Alberts will present “The Gen AI Revolution," followed by happy hour and a complimentary book signing.

This event is Thursday, Sept. 25, from 5:30-7:30 p.m. at the Ion. Register here.

Texas is the 4th hardest working state in America, report finds

Ranking It

It's no secret that Texans are hardworking people. To align with the Labor Day holiday, a new WalletHub study asserts that the Lone Star State is one of the five most hardworking states in America for 2025.

The report ranked Texas the fourth most hardworking state this year, indicating that its residents are working harder than ever after the state fell into seventh place in 2024. Texas previously ranked No. 4 in 2019 and 2020, slipped into No. 5 in 2021 and 2022, then continued falling into sixth place in 2023. But now the state is making its way back to the top of the list.

WalletHub's analysts compared all 50 states based on "direct" and "indirect" work factors. The six "direct" work factors included each state's average workweek hours, employment rates, the share of households where no adults work, the share of workers leaving vacation time unused, and other data. The four "indirect" work factors consisted of workers' average commute times, the share of workers with multiple jobs, the annual volunteer hours per resident, and the average leisure time spent per day.

North Dakota landed on top as the most hardworking state in America for 2025 for another year in a row, earning a score of 66.17 points out of a possible 100. For comparison, Texas ranked No. 4 with 57.06 points. Alaska (No. 2), South Dakota (No. 3), and Hawaii (No. 5) round out the top five hardest working states.

Across the study's two main categories, Texas ranked No. 5 in the "direct" work factors ranking, and earned a respectable No. 18 rank for its "indirect" work factors.

Broken down further, Texans have the second-longest average workweek hours in America, and they have the 12th best average commute times. Texans have the 6th lowest amount of average leisure time spent per day, the report also found.

According to the study's findings, many Americans nationwide won't take the chance to not work as hard when presented with the opportunity. A 2024 Sorbet PTO report found 33 percent of Americans' paid time off was left unused in 2023.

"While leaving vacation time on the table may seem strange to some people, there are plenty of reasons why workers choose to do so," the report's author wrote. "Some fear that if they take time off they will look less dedicated to the job than other employees, risking a layoff. Others worry about falling behind on their work or are concerned that the normal workflow will not be able to function without them."

The top 10 hardest working states are:

  • No. 1 – North Dakota
  • No. 2 – Alaska
  • No. 3 – South Dakota
  • No. 4 – Texas
  • No. 5 – Hawaii
  • No. 6 – Virginia
  • No. 7 – New Hampshire
  • No. 8 – Wyoming
  • No. 9 – Maryland
  • No. 10 – Nebraska
---

This story originally appeared on CultureMap.com.

View All Listings